sheKnows

sheKnows
A digital health platform empowering women to understand and manage their health.
About
What does sheKnows do?
sheKnows aims to address the under-research and misdiagnosis prevalent in women's health. The platform provides women with tools to understand their bodies, discover effective solutions, and connect with a supportive community, ultimately helping them feel better.
What is sheKnows's revenue?
StartupHub estimates sheKnows's annual revenue at $361K (range $212K to $947K, 69% confidence), based on comparable companies in the sector.
When was sheKnows founded?
sheKnows was founded in 2022.
What industry does sheKnows operate in?
sheKnows operates in Healthcare, FemTech, HealthTech, Digital Health, Women's Health, Mental Health Tech.
How many employees does sheKnows have?
sheKnows has approximately 2 people on record.
What is sheKnows's current status?
sheKnows's current operating status is: Inactive.
AI-powered platform for healthcare providers to manage patient WhatsApp messages efficiently.
AI-powered platform for personalized weight management and health coaching.
Clinical Trial Discovery by ENSCORE.
An independent research reference providing accessible, accurate, and transparent information on bioactive peptides and peptide science.
Medbytes provides doctors with a personalized platform for high-impact medical research and news in their specialty.
SYLARIS™ offers premium wearable wellness patches and clinical-grade skincare designed for effortless, intentional, and beautifully designed self-care rituals.
Provider-supervised peptide therapy, NAD+ support, and cognitive enhancement for cellular renewal, recovery, and healthy aging.
Purpose-built WordPress plugins for healthcare and the agencies that serve them.
An entrant is a company tagged HealthTech whose domain was first registered in the window, counted from registry records in the StartupHub directory. 6 of them registered in the last 30 days. Registry detection runs two to three weeks behind registration, so recent weeks are a floor.
No comments yet. Be the first to share your take.